Ownership and insider activity for Molecular Partners AG (MOLN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema.
Price
| Price | $3.92 |
| Market Cap | $147M |
| Exchange | NASDAQ |
| Country | CH |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $149.7M | $131.3M | $99.0M | $75.7M | $133.7M | $71.8M | $87.9M | $67.3M | $63.9M | $82.7M |
| Short-term Investments | $30.5M | $9.7M | 0 | $19.4M | $40.0M | $61.0M | $161.2M | $119.6M | $85.6M | $10.4M |
| Receivables | $844000 | $1.2M | $51.6M | $2.5M | $2.8M | $25.7M | $1.7M | $3.1M | $286000 | $1.9M |
| Inventory | 0 | -$9.4M | -$2.3M | -$486000 | -$199000 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $181.6M | $142.5M | $153.3M | $99.9M | $177.8M | $164.2M | $254.8M | $192.5M | $154.3M | $96.9M |
| Property, Plant & Equipment | $2.5M | $1.9M | $1.5M | $4.2M | $9.4M | $8.1M | $7.2M | $5.7M | $4.2M | $5.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $47000 | $27000 | $382000 | $772000 | $347000 | $330000 | $271000 | $212000 | $49000 | $2000 |
| Total Assets | $184.1M | $144.4M | $155.2M | $104.9M | $187.5M | $172.7M | $262.3M | $198.4M | $158.5M | $102.1M |
| Accounts Payable | $1.0M | $716000 | $2.1M | $2.0M | $2.8M | $4.9M | $997000 | $410000 | $679000 | $937000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $15.8M | $14.1M | $36.9M | $28.6M | $57.7M | $46.9M | $17.3M | $14.4M | $10.8M | $11.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $48.3M | $27.7M | $63.5M | $50.8M | $80.3M | $65.4M | $27.1M | $21.9M | $16.9M | $21.8M |
| Retained Earnings | -$37.3M | -$60.7M | -$89.9M | -$130.9M | -$195.2M | -$250.9M | -$127.8M | -$191.8M | -$246.3M | -$311.8M |
| Total Equity | $135.8M | $116.7M | $91.7M | $54.1M | $107.2M | $107.3M | $235.2M | $176.4M | $141.6M | $80.3M |
| Total Debt | 0 | 0 | 0 | $2.5M | $7.2M | $6.0M | $4.8M | $3.7M | $2.4M | $3.6M |
| Net Debt | -$180.2M | -$141.1M | -$99.0M | -$92.5M | -$166.5M | -$126.8M | -$244.3M | -$183.2M | -$147.0M | -$89.4M |
| Working Capital | $165.8M | $128.4M | $116.5M | $71.3M | $120.1M | $117.3M | $237.5M | $178.0M | $143.5M | $85.8M |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 7.27 |
Profitability
| Return on Equity | -67.67% |
| Return on Invested Capital | -76.91% |
| Return on Assets | -67.68% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALEC · APLT · CRBP · CRDF · ELTX · MIST · NKTX
Explore sector: Healthcare · Biotechnology
More sections of MOLN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks